Validated, tissue-specific library enables customisable and controllable liver-targeted gene expression with high specificity and minimal off-target activity in muscle tissue ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS).
Higher CD4⁺ T-cell recovery correlated with more rapid neutrophil engraftment Accelerated NK-cell recovery: Natural killer ...
Southampton PhD student Lara Graham’s immunotherapy research has taken on new meaning after it helped her mother’s cancer ...
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...
A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE ® natural killer (NK ...
Explore the groundbreaking research on brain organoids that mimics glioblastoma in the human brain for better treatment ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
The company received FDA clearance to launch a Phase I trial of its therapy, which it says can overcome safety and efficacy concerns related to systemic AAV delivery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results